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Beyond the Dopamine Receptor: Review
the DARPP-32/Protein
Phosphatase-1 Cascade
Dopamine and the Neostriatum
A major target for midbrain dopaminergic neurons is the
neostriatum (Figure 2). Compared to other brain regions,
the neostriatum is remarkably homogeneous. About
95% of all neostriatal neurons have a similar morphology
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and are referred to as medium-sized spiny neurons.
They are the only known projection neurons in the neo-
striatum, and therefore function to integrate all input toIntroduction
this brain region. DARPP-32 is expressed in very highOf the many slow-acting neurotransmitters utilized by
concentration (z50 mM) in virtually all medium spinythe mammalian central nervous system, dopamine has
neurons (Ouimet et al., 1984, 1998) (Figure 2). Mediumreceived by far the most attention. There are major medi-
spiny neurons contain both D1 class (D1, D5) and D2 classcal reasons for this interest in understanding the nature
(D2, D3, D4) dopamine receptors (Sibley and Monsma,of dopaminergic neurotransmission. Parkinson's dis-
1992). Analysis of dopamine action is complicated byease is attributable to a selective degeneration of mid-
the differential distribution of these receptors. While stillbrain nigrostriatal dopaminergic neurons. Huntington's
controversial, the prevailing view is that D1 and D2 dopa-chorea is caused by a deterioration of dopaminoceptive
mine receptors are largely segregated in two subpopula-projection neurons in the neostriatum. Virtually all anti-
tions of medium spiny neurons (Gerfen et al., 1990;schizophrenic drugs in current use act as antagonists
Hersch et al., 1995; Yung et al., 1995). The D1 class areat a major subclass of dopamine receptors, supporting
expressed predominantly in striatonigral neurons (directthe conjecture that aberrations in dopaminergic neuro-
pathway) and are colocalized with the neuropeptidestransmission contribute to the symptomatology of schizo-
dynorphin and substance P. In contrast, the D2 classphrenia. Attention deficit hyperactivity disorder (ADHD)
of receptors are found predominantly in striatopallidalsymptoms are greatly alleviated by drugs that regulate
neurons (indirect pathway) and are colocalized with en-dopaminergic transmission. Finally, drugs of abuse of
kephalin. However, based on physiological analysis ofthe cocaine, amphetamine, and opiate classes, as well
the actions of D1 and D2 agonists (see below), andas nicotine and alcohol, achieve some of their addictive
analysis of mRNA expression, it appears likely that aactions by modifying dopaminergic transmission.
significant subpopulation of medium spiny neurons ex-Despite the widespread interest in, and clinical impor-
press both D1 and D2 classes of receptors (Surmeiertance of, dopaminergic signaling, little was known until
et al., 1996).recently concerning the molecular and cellular basis for
Medium spiny neurons contain both NMDA and non-the actions of dopamine on its target cells. In this article,
NMDA classes of glutamate receptors and receive majorwe review recent studies that demonstrate that a phos-
excitatory inputs from glutamate-containing corticostri-phoprotein, known by the acronym DARPP-32 (dopa-
atal nerve terminals (reviewed by Gerfen, 1992; Smithmine and cyclic adenosine 39,59-monophosphate-regu-
et al., 1998). In addition to glutamate and dopamine,lated phosphoprotein, 32 kDa), plays a central role in
medium spiny neurons receive an inhibitory input fromthe biology of dopaminoceptive neurons. Dopamine and
GABA-containing nerve terminals via recurrent collater-numerous other neurotransmitters that have been found
als (Gerfen, 1992; Smith et al., 1998). Adenosine A2Ain the neostriatum and shown to have physiological ef-
receptors are expressed specifically on striatopallidalfects on dopaminoceptive neurons alter the phosphory-
neurons (Svenningsson et al., 1997), where they arelation and/or dephosphorylation of DARPP-32 (Figure
coexpressed with D2 receptors. Opiate receptors (Man-1). In its phosphorylated but not dephosphorylated form,
sour et al., 1987), as well as receptors for neuropeptidesDARPP-32 is an extremely potent inhibitor of protein
such as cholecystokinin (CCK) and neurotensin (Fuxephosphatase-1 (PP-1), a major multifunctional serine/
et al., 1995; Ferraro et al., 1998), are also found in thethreonine protein phosphatase in the brain. PP-1, in turn,
striatum and have been shown to influence the activityregulates the phosphorylation state and activity of many
of medium spiny neurons. The striatum also contains adownstream physiological effectors, including various
small population of interneurons, including large aspinyneurotransmitter receptors and voltage-gated ion chan-
neurons that release acetylcholine, and several types ofnels. Studies of mice lacking the DARPP-32 gene have
medium aspiny neurons that contain somatostatin andprovided convincing evidence that this protein plays an
neuropeptide Y (Figueredo-Cardenas et al., 1996).essential role in mediating the actions and interactions
of dopamine and other neurotransmitters that act on
Convergent Actions of Dopamine and Otherdopaminoceptive neurons (Figure 1 and Table 1). These
Neurotransmitters on the Phosphorylation/studies have also shown that the DARPP-32/PP-1 cas-
Dephosphorylation of DARPP-32cade is a major target for psychostimulants and anti-
Regulation of DARPP-32 Phosphorylationschizophrenic drugs.
Dopamine and D1-selective agonists act on the striato-
nigral subpopulation of medium spiny neurons express-
ing the D1 class of receptors to increase the activity of* To whom correspondence should be addressed (e-mail: greengd@
rockvax.rockefeller.edu). adenylyl cyclase, increase cAMP formation, stimulate
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Figure 1. Central Role of the DARPP-32/
PP-1 Pathway in Signal Transduction in Me-
dium Spiny Neurons
The DARPP-32/PP-1 pathway integrates in-
formation from a variety of neurotransmitters
and produces a coordinated response involv-
ing numerous downstream physiological ef-
fectors. Green arrows indicate activating steps
and red arrows indicate inhibitory steps.
DARPP-32 phosphorylation at Thr-34 by PKA
is regulated by the actions of various neuro-
transmitters, principally dopamine acting at
D1 receptors, but also adenosine acting at
A2A receptors and VIP acting at VIP receptors.
PKG activated in response to NO also phos-
phorylates Thr-34 of DARPP-32. In medium
spiny neurons that coexpress D1 and D2
classes of dopamine receptor, activation of
D2 receptors acts to decrease cAMP levels.
In medium spiny neurons that coexpress
adenosine A2A receptors and D2 receptors,
activation of D2 receptors also acts to de-
crease cAMP levels (not shown). Opiates act-
ing at either m or d receptors decrease cAMP
levels in cells stimulated with D1 agonists or
adenosine A2A agonists, respectively. DARPP-
32 phosphorylated at Thr-34 is dephosphory-
lated by PP-2B, a Ca21/calmodulin-depen-
dent protein phosphatase. PP-2B activity is
activated by a number of different neuro-
transmitter receptors, principally following
Ca21 influx mediated by glutamate acting at NMDA receptors. Glutamate acting at AMPA receptors also stimulates DARPP-32 dephosphorylation
by PP-2B, by an indirect mechanism that involves depolarization of the neuron and influx of Ca21. Activation of D2 receptors also leads to
an increase in Ca21 levels, via an unidentified mechanism, and increased activity of PP-2B. In contrast, GABA acting at GABAA receptors
stimulates DARPP-32 phosphorylation by hyperpolarization of the neuron, decreased influx of Ca21, and inactivation of PP-2B. Neurotensin
acts to increase DARPP-32 phosphorylation by increasing the release of dopamine. CCK decreases DARPP-32 phosphorylation by increasing
glutamatergic neurotransmission. The psychomotor stimulants cocaine and amphetamine increase DARPP-32 phosphorylation by increasing
dopaminergic neurotransmission. All antipsychotic drugs achieve certain of their clinical effects via antagonism of the D2 class of dopamine
receptors, an action leading to an increase in the state of phosphorylation of DARPP-32. Phospho-DARPP-32, by inhibiting the activity of PP-
1, acts in a synergistic manner with different protein kinases (primarily PKA and PKC; not shown) to increase the level of phosphorylation of
various downstream effector proteins. The resulting increase in phosphorylation is associated with increased activity of NMDA and AMPA
glutamate receptors, L-, N-, and P-type Ca21 channels, and CREB and with decreased activity of GABAA receptors, Na1 channels, and the
Na1/K1-ATPase.
cAMP-dependent protein kinase (PKA) (Stoof and Ke- rapidly in the presence of a D1 agonist (Nishi et al.,
1997). Adenosine, via A2A receptors, also activates PKAbabian, 1981), and phosphorylate DARPP-32 at a single
site, Thr-34 (Figure 1). Under basal conditions, the stoi- and increases DARPP-32 phosphorylation (Svennings-
son et al., 1998). The effect of an A2A receptor-specificchiometry of phosphorylation of DARPP-32 at Thr-34 in
neostriatal slice preparations is low, but this increases agonist is similar in magnitude to that of a D1 receptor
Table 1. Attenuated Responses to Dopamine, Psychostimulants, and Antipsychotic Drugs in DARPP-32 Knockout Mice
Stimulus Parameter Example
Dopamine Ion pump Na1/K1-ATPase inhibition
Dopamine Ion channel Na1 channel inhibition
N/P-type Ca21 channel inhibition
Dopamine Neurotransmitter release GABA release
Dopamine release
Dopamine Neurotransmitter receptors NMDA (NR1) receptor phosphorylation
AMPA (GluR1) receptor phosphorylation/conductance
GABAA receptor phosphorylation/conductance
Dopamine, cocaine, amphetamine Immediate-early genes c-fos induction
Chronic c-fos-related antigen induction
Cocaine, amphetamine Brain damage Reactive gliosis
Cocaine, amphetamine Locomotor activity Acute activity response
Antipsychotics Locomotor activity Catalepsy
Apomorphine Motor behavior Cage climbing
A detailed description of these response deficits can be found in Fienberg et al. (1998), Snyder et al. (1998), Hiroi et al. (1999), and Nishi et
al. (1999).
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both PP-2A and the Ca21/calmodulin-dependent phos-
phatase PP-2B (or calcineurin) (King et al., 1984). PP-
2B is highly enriched in medium spiny neurons (Goto et
al., 1986) and plays a prominent role in the dephosphory-
lation of DARPP-32 in intact cells (Nishi et al., 1997).
In addition, PP-2B acts synergistically with PP-2A to
regulate the dephosphorylation of DARPP-32 (Nishi et
al., 1999). The ability of the cAMP/PKA pathway to in-
crease DARPP-32 phosphorylation in medium spiny
neurons is abolished by NMDA (Halpain et al., 1990).
This effect of NMDA is reduced by cyclosporin A, a
highly specific PP-2B inhibitor. Similar results have been
obtained following stimulation of the AMPA class of
glutamate receptors (Snyder et al., 1995, Soc. Neurosci.,
abstract). Thus, NMDA and AMPA receptors, which are
Figure 2. DARPP-32 and Organization of the Neostriatum present on all medium spiny neurons, participate in glu-
Simplified depiction of neostriatal connectivity, superimposed on tamate-mediated dephosphorylation of DARPP-32, prob-
DARPP-32 immunostaining in a rat parasaggital section. The dark ably through Ca21-dependent activation of PP-2B.
immunoperoxidase staining for DARPP-32 is due to the very high
Activation of D2 receptors also decreases the statelevel of expression in dopaminoceptive neostriatal medium spiny
of phosphorylation of DARPP-32 (Nishi et al., 1997; Lind-neurons and their axonal projections. Medium spiny neurons receive
their major excitatory input from glutamatergic cortical projections skog et al., 1998). Quinpirole, a D2 receptor agonist,
(and thalamus; not shown). Medium spiny GABAergic output is di- decreases D1 agonist±stimulated phosphorylation of
rected to substantia nigra via both direct and indirect pathways. DARPP-32, an effect that is blocked by inhibition of PP-
Neurons of the direct striatonigral pathway preferentially express
2B. This action of quinpirole may occur in a subpopula-D1 dopamine receptors, while those of the indirect pathway project
tion of medium spiny neurons of the striatonigral projec-to globus pallidus and preferentially express D2 dopamine recep-
tors. Activation of the trisynaptic (Nst/GP/STN/SNr) indirect pathway tion, which contain both D1 and D2 receptors (Surmeier
results in disinhibition of SNr GABAergic output neurons, in opposi- et al., 1996; Nishi et al., 1997). Alternatively, the D2 re-
tion to the inhibitory influence of input from the direct striatonigral ceptor±mediated effect on D1 receptor activation may
pathway. GABAergic output from the SNr returns via a glutamatergic
occur via interactions between striatopallidal and stria-thalamic relay to cortex. Dopaminergic input into this synaptic net-
tonigral neurons (Gerfen et al., 1990; Harsing and Zig-work comes from neurons of the SNc that project to dorsal neostria-
mond, 1997; Le Moine et al., 1997; Lindskog et al., 1998).tum. Dopaminergic neurons with cell bodies in the SNc and den-
drites in the SNr receive axodendritic innervation from terminals of Quinpirole also strongly inhibits the phosphorylation
the striatonigral pathway. Dopaminergic input to ventral striatum of DARPP-32 induced by an adenosine A2A receptor ago-
from the ventral tegmentum is not depicted. Color scheme: green, nist (Lindskog et al., 1998), by a mechanism that does
glutamatergic neurons; red, GABAergic neurons; blue, dopaminer-
not appear to involve PP-2B. This effect is likely to takegic neurons. Abbreviations: Ctx, cortex; Nst, neostriatum; GP, glo-
place in the striatopallidal neurons in which these twobus pallidus; STN, subthalamic nucleus; SNr, substantia nigra pars
reticulata; SNc, substantia nigra pars compacta; Th, thalamus. receptors are coexpressed, via a Gi-mediated mecha-
nism (Stoof and Kebabian, 1981; Huff et al., 1998). Impor-
tantly, the regulation of DARPP-32 phosphorylation mayagonist, and the effects of A2A and D1 agonists are addi-
tive. Since adenosine A2A receptors are selectively ex- be responsible for mediating the antagonistic relation-
pressed in striatopallidal neurons (Svenningsson et al., ship of dopamine and adenosine in this subpopulation
1997), DARPP-32 may be phosphorylated by PKA in of medium spiny neurons (Ferre et al., 1997).
distinct subpopulations of medium spiny neurons that In addition to glutamate and dopamine, several other
express either D1 or A2A receptors. neurotransmitters and neurohormones regulate DARPP-
DARPP-32 phosphorylation is also increased by a 32 dephosphorylation in medium spiny neurons (Figure
number of other neurotransmitters that stimulate cAMP 1). In striatal slices, GABA induces a rapid, transient
formation, including vasoactive intestinal peptide (VIP) increase in DARPP-32 phosphorylation that is abolished
(Girault et al., 1988). Neurotensin increases DARPP-32 by blockade of GABAA, but not GABAB, receptors (Sny-
phosphorylation, possibly via stimulation of dopamine der et al., 1994). This increase in DARPP-32 phosphory-
release. In vitro, Thr-34 of DARPP-32 is an excellent lation is likely to be caused by a decrease in the activity
substrate for phosphorylation by cGMP-dependent pro- of PP-2B. CCK, which is abundant in corticostriatal
tein kinase (PKG) (Hemmings et al., 1984b). Treatment of
nerve terminals in neostriatum, also regulates the state
slices from substantia nigra with sodium nitroprusside,
of phosphorylation of DARPP-32 (Snyder et al., 1993).which spontaneously breaks down to form nitric oxide
CCK, through activation of CCKB receptors, decreases(NO), increases phosphorylation of DARPP-32 at Thr-
forskolin-induced phosphorylation of DARPP-32, an ef-34 via activation of the soluble form of guanylyl cyclase,
fect that is blocked by an NMDA receptor antagonist.synthesis of cGMP, and selective stimulation of PKG
These and other data suggest that CCK stimulates theactivity (Tsou et al., 1993).
release of excitatory amino acids from glutamate-con-Regulation of DARPP-32 Dephosphorylation
taining corticostriatal nerve terminals and/or aspartate-Dephosphorylation of DARPP-32 plays an equally im-
containing interneurons, which in turn stimulate gluta-portant role in the modulation of the DARPP-32/PP-1
mate receptors on medium spiny neurons (Snyder et al.,signaling cascade (Figure 1). In vitro, DARPP-32 phos-
phorylated at Thr-34 is efficiently dephosphorylated by 1993).
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Figure 3. Localization of Spinophilin to Den-
dritic Spines
(Top) Confocal laser scanning microscope
image of rat neostriatum (courtesy of Charles
C. Ouimet). Small arrows point to spinophilin-
labeled puncta (red). Large arrows point to
MAP-2-labeled dendrites (green). Asterisks
mark somata. The nonoverlapping staining
pattern reflects the distinct localization of
spinophilin and MAP-2 to spines and den-
drites, respectively. Calibration bar, 10 mm.
(Bottom left) Immunoelectron microscope im-
age revealing spinophilin labeling (dark) in the
head of a dendritic spine innervated by two
unstained axon terminals. Abbreviations:
TER, axon terminal; DEN, dendrite. Calibra-
tion bar, 100 nm.
(Bottom right) Schematic representation of
postulated spinophilin macromolecular com-
plex in the dendritic spine. PP-1 is situated
to control the state of phosphorylation and
activity of multiple potential substrates, in-
cluding the actin cytoskeleton, ribosomal S6
kinase (p70rsk), and transmembrane proteins
such as neurotransmitter receptors and ion
channels that might bind to the PDZ domain
of spinophilin. Abbreviation: CC, coiled-coil
domain of spinophilin involved in self-associ-
ation.
Interaction of PP-1 with Targeting Subunits likely to come from a second PP-1 binding protein that
is related in structure to spinophilin (Nakanishi et al.,Localization of PP-1 to Dendritic Spines
In addition to its regulation by DARPP-32, PP-1 also 1997). This protein was identified based on its ability to
bind to F-actin and was named neurabin (neuronal actininteracts with a distinct group of proteins, termed tar-
geting subunits, that serve to localize the catalytic sub- binding protein). Subsequently, spinophilin was also
shown to bind to F-actin (and based on its similarityunit of PP-1 to specific subcellular compartments and
also to modulate PP-1 activity toward protein substrates to neurabin was referred to as neurabin-II/spinophilin)
(Satoh et al., 1998). Both spinophilin and neurabinat the targeted sites (Hubbard and Cohen, 1993; Faux
and Scott, 1996). Biochemical studies have shown that possess consensus sites for phosphorylation within the
actin binding region, raising the possibility that the inter-PP-1, though present in all subcellular fractions, is par-
ticularly abundant in the postsynaptic density fraction action with actin is modulated following synaptic stimu-
lation. PP-1 has been implicated in the control of the(Shields et al., 1985; Sim et al., 1994). Consistent with
this, immunoelectron microscopy reveals a high degree actin±myosin cytoskeleton in nonneuronal cells (Fernan-
dez et al., 1990; Kaibuchi, 1999). Therefore spinophilin,of enrichment of PP-1 in dendritic spines (Ouimet et
al., 1995), postsynaptic specializations that receive the PP-1, and possibly neurabin are well situated to regulate
the dense actin filament network found in dendriticmajority of excitatory input in the brain (Gray, 1959). A
yeast two-hybrid screen led to the isolation of a pre- spines, and may control spine morphology and dynam-
ics and thus synaptic efficacy (Harris and Kater, 1994).viously unidentified neuronal PP-1 targeting protein that
is also highly enriched in dendritic spines. This protein, PP-1 Targeting by PDZ Domain±Containing Proteins
Spinophilin and neurabin-I have the potential to interactnamed spinophilin, colocalizes with PP-1 and accounts
for at least a part of the enrichment of PP-1 in spines with additional synaptic proteins (Figure 3). Both contain
COOH-terminal stretches of predicted coiled-coil ter-(Figure 3) (Allen et al., 1997).
A further contribution to PP-1 synaptic targeting is tiary structure that may mediate self-association and/
Review
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Figure 4. Interaction of PP-1 with DARPP-32 and Targeting Proteins
(A) Schematic diagram showing the interaction of the inhibitory and docking domains of DARPP-32 with PP-1. The inhibition of PP-1 by
phospho-DARPP-32 occurs via a two-site interaction involving the binding of phospho-Thr-34 to the active site of the enzyme (active site
interaction) and the interaction of residues 7±11 of DARPP-32 with a region of PP-1 removed from the active site (docking site interaction).
(B) A conserved docking motif is involved in the binding of DARPP-32 and targeting proteins to PP-1. The docking motif, highlighted in blue,
contains a BBHXH motif (where B indicates a basic amino acid, H indicates a hydrophobic amino acid, and X indicates a variable amino acid).
Ser-461 adjacent to the docking motif of neurabin (McAvoy et al., 1999) and Ser-67 within the docking motif of the glycogen binding subunit
of PP-1 (GM) (Hubbard and Cohen, 1993) are phosphorylated by PKA resulting in inhibition of binding to PP-1.
or heterologous interactions. In addition, both proteins Studies of a number of PP-1 targeting subunits, in-
cluding spinophilin and neurabin (Egloff et al., 1997;contain single PDZ domains, structures that have at-
tracted much attention due to their role in coupling to Hsieh-Wilson et al., 1999; McAvoy et al., 1999), have
revealed that they contain a common structural motiftransmembrane proteins. For example, the PSD-95 fam-
ily of PDZ domain±containing proteins have been shown related to the KKIQF sequence that is critical for binding
to PP-1. This ªdocking motifº consists of one or moreto bind to NMDA receptors and to Shaker-type K1 chan-
nels, promoting clustering of these receptors (Sheng basic amino acids, followed by two hydrophobic resi-
dues that are separated by a variable amino acid (Figureand Wyszynski, 1997; Craven and Bredt, 1998; O'Brien
et al., 1998). By analogy, spinophilin and neurabin, via 4B). The presence of a conserved docking motif in
DARPP-32 and many PP-1 targeting subunits predictstheir PDZ domains, may bind directly to neurotransmit-
ter receptors or ion channels present at the synapse and that there will be mutually exclusive binding of the inhibi-
tor and the targeting proteins to the catalytic subunitthus bring PP-1 into the vicinity of relevant substrates.
However, recent studies have shown that p70 ribosomal of PP-1. This has significant functional implications for
AMPA receptor regulation (see Figure 7).S6 kinase binds to the PDZ domain of neurabin (Burnett
et al., 1998) and spinophilin (P. B. A. and P. E. Burnett, The identification of the docking motif has allowed
the development of peptides that can antagonize theunpublished data). To date, no role in the regulation of
synaptic transmission has been ascribed to p70 ribo- interaction of phospho-DARPP-32 or targeting subunits
with PP-1 (Egloff et al., 1997; Kwon et al., 1997; Hsieh-somal S6 kinase. An intriguing possibility is that this
complex may be involved in the regulation of local pro- Wilson et al., 1999) (see below). This provides an ap-
proach to the development of novel nonpeptide mole-tein synthesis in the dendritic spine, a phenomenon that
is thought to be responsive to changes in synaptic activ- cules that could interact with the docking site without
inhibiting PP-1 activity. The three-dimensional structureity and may underlie certain forms of plasticity (Steward,
1997; Tiedge et al., 1999). of the catalytic subunit of PP-1 has been determined
(Egloff et al., 1995; Goldberg et al., 1995), and the molec-
ular basis for the interaction of the docking motif of theStructural Basis for the Interaction of PP-1
with DARPP-32 and Targeting Subunits glycogen binding subunit with PP-1 has been elucidated
(Egloff et al., 1997). The determination of additional de-Phosphorylation of Thr-34 in DARPP-32 by PKA con-
verts the protein into a potent inhibitor of PP-1 with an tails of the interactions of PP-1 with phospho-DARPP-
32, and with neuronal PP-1 targeting proteins, mayIC50 of z1029 M (Hemmings et al., 1984a). A variety of
structure±function studies have indicated that two do- prove useful in the development of novel compounds
for the treatment of Parkinson's disease, schizophrenia,mains of DARPP-32 are involved in the inhibition of PP-1
(Figure 4A) (Hemmings et al., 1990; Desdouits et al., and other disorders of dopamine signaling pathways.
1995a; Kwon et al., 1997; Huang et al., 1999). An inhibi-
tory domain, consisting of phospho-Thr-34 and the sur- Regulation of a Protein Phosphatase Cascade
by Multisite Phosphorylation of DARPP-32rounding residues, is likely to occupy, or bind close to,
the active site of the enzyme in a manner in which access A number of studies now indicate that, in addition to
phosphorylation of Thr-34 by PKA, DARPP-32 is phos-to phosphorylated substrate is prevented. A second do-
main of DARPP-32, consisting of residues 7±11 (KKIQF), phorylated on serine residues, and that serine phos-
phorylation modulates inhibition of PP-1. In intact neu-interacts with PP-1 at a site removed from the active
site but is critical for inhibition (Figure 4A). rons, DARPP-32 is highly phosphorylated on Ser-102
Neuron
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Figure 5. Regulation of a Protein Phosphatase Cascade by Multisite Phosphorylation of DARPP-32
(A) Phosphorylation sites in DARPP-32. DARPP-32 is phosphorylated at Thr-34 by PKA (and PKG; not shown), at Ser-102 by CK2, and at Ser-
137 by CK1. Phosphorylation of DARPP-32 by CK2 increases the rate of phosphorylation of Thr-34 by PKA (green arrow indicates positive
effect); phosphorylation of DARPP-32 by CK1 decreases the rate of dephosphorylation of Thr-34 by PP-2B (red arrow indicates negative
effect). Phospho-Ser-137 is preferentially dephosphorylated by PP-2C. NH2-terminal domains of DARPP-32 that bind to PP-1 are shown in
color.
(B) Protein phosphatase cascade involving PP-2C, PP-2B, and PP-1. The dephosphorylation of Ser-137 by PP-2C acts to increase the activity
of PP-2B toward phospho-Thr-34, leading to activation of PP-1.
and Ser-137. Ser-102 is phosphorylated by protein ki- viewed by Kotter, 1994; Lovinger and Tyler, 1996; Cep-
eda and Levine, 1998; Nicola et al., 1999). Dopaminenase CK2 (casein kinase II) and Ser-137 is phosphory-
lated by protein kinase CK1 (casein kinase I) (Figure can either enhance (Cepeda et al., 1993) or inhibit (Cala-
bresi et al., 1987; Cepeda et al., 1993; but see also5A). Phosphorylation of Ser-102 of DARPP-32 by CK2
increases the efficiency of phosphorylation of Thr-34 by Nicola and Malenka, 1998) glutamate-evoked excitation,
effects that are dependent on both the subtype of dopa-PKA but not PKG (Girault et al., 1989). In vitro, phosphor-
ylation of Ser-137 by CK1 decreases the rate of dephos- mine receptor and the subtype of glutamate receptor
involved. The effect of dopamine on the excitability ofphorylation of Thr-34 by PP-2B, and in striatal slices
DARPP-32 phosphorylated at Ser-137 is phosphorylated medium spiny neurons is also dependent on the mem-
brane potential in the target neuron (Wilson, 1993; Wil-to a higher level at Thr-34 (Desdouits et al., 1995b, 1995c).
The overall consequence of phosphorylation of DARPP- son and Kawaguchi, 1996; Hernandez-Lopez et al.,
1997). D1 and D2 receptor agonists have an inhibitory32 by CK1 or CK2 in intact cells is to increase the state
of phosphorylation of Thr-34. The physiological effect effect on neurons in a hyperpolarized ªdown state,º
most likely mediated by effects on Ca21, Na1, and K1of these two phosphorylation events is therefore to po-
tentiate signaling through the dopamine/D1/cAMP/PKA/ currents (reviewed by Cepeda and Levine, 1998). In con-
trast, D1 receptor agonists have an excitatory effectDARPP-32/PP-1 pathway and to reduce signaling through
the glutamate/Ca21/PP-2B/DARPP-32/PP-1 pathway. on neurons in a depolarized ªup state,º which may be
mediated by enhancement of L-type Ca21 currents (Her-Studies in vitro, and in intact cells, indicate that Ser-
137 is preferentially dephosphorylated by PP-2C (Des- nandez-Lopez et al., 1997; Cepeda et al., 1998). Therefore,
the neuromodulatory role of dopamine on glutamatedouits et al., 1998). The finding that Ser-137 phosphory-
lation influences the ability of PP-2B to act on Thr-34 transmission is contingent on the complex regulation of
multiple ionic conductances.reveals a hierarchical relationship among PP-2C, PP-
2B, and PP-1 (Figure 5B). Thus, PP-2C activity toward A variety of biochemical and electrophysiological
Ser-137 increases the ability of PP-2B to dephosphory- studies have indicated that the DARPP-32/PP-1 cas-
late phospho-Thr-34. In turn, dephosphorylation of Thr- cade plays a key role in mediating the effects of dopa-
34 by PP-2B leads to the generation of active PP-1. mine on ionic conductances in these cells (Figure 1).
Several protein kinase cascades have been described Moreover, strong support for this conclusion has been
that are critical for signal amplification or for the integra- obtained by the characterization of mice with targeted
tion of multiple inputs from distinct extracellular mes- deletion of the DARPP-32 gene (Table 1). Various physi-
sengers (Blumer and Johnson, 1994). The hierarchical ological targets for the DARPP-32/PP-1 cascade have
relationship described here is mechanistically distinct been identified, including ligand-gated ion channels,
from those kinase cascades, since it requires DARPP- voltage-gated ion channels, and the electrogenic ion
32. However, the physiological relationship between PP- pump Na1/K1-ATPase. A few examples will be dis-
2C, PP-2B, and PP-1 that is mediated by DARPP-32 cussed.
results in a functionally analogous protein phosphatase NMDA-Type Glutamate Receptors
cascade. Dopamine and D1 agonists increase the phosphoryla-
tion of the NR1 glutamate receptor subunit in medium
spiny neurons via a cAMP/PKA-dependent pathwayRole of the DARPP-32/PP-1 Cascade in Mediating
the Physiological Actions of Dopamine (Fienberg et al., 1998; Snyder et al., 1998). This effect
of dopamine is significantly attenuated in neurons fromElectrophysiological studies have revealed a complex
role for dopamine in the modulation of excitatory gluta- DARPP-32 knockout mice. The phosphorylation of the
NR1 subunit is likely to occur through a synergisticmatergic transmission in medium spiny neurons (re-
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Figure 6. Synergistic Regulation of Physio-
logical Effects by a Mechanism Involving In-
creased Phosphorylation and Decreased De-
phosphorylation
In the examples shown, NMDA glutamate
receptors and L-type Ca21 channels are regu-
lated by PKA and the DARPP-32/PP-1 path-
way. Dopamine, by activation of D1 recep-
tors, increases cAMP levels leading to
increased activity of PKA. PKA directly phos-
phorylates NMDA receptors (the NR1 subunit
is a likely substrate) and L-type Ca21 channels
(green arrows indicate activation). PKA also
phosphorylates DARPP-32 at Thr-34 leading
to inhibition of PP-1 (red arrows indicate inhi-
bition). PP-1 dephosphorylates either NMDA
receptors or L-type Ca21 channels, leading to
their inactivation. Inhibition of PP-1 by phos-
pho-DARPP-32 acts in a synergistic manner
with PKA to increase the state of phosphory-
lation and activity of NMDA receptors and
L-type Ca21 channels. NMDA receptors and
L-type Ca21 channels are both voltage-
dependent Ca21 channels and act in an inter-
dependent manner to increase intracellular
Ca21 levels.
mechanism that involves increased phosphorylation of AMPA-Type Glutamate Receptors
Ser-897 in the channel by PKA (Tingley et al., 1997) The activity of the AMPA receptor is known to be potenti-
and decreased dephosphorylation of the channel by a ated by phosphorylation of the GluR1 subunit on multi-
mechanism involving PKA-dependent phosphorylation ple sites at the COOH terminus by enzymes that include
of DARPP-32 and inhibition of PP-1 (Figure 6). PKA (Roche et al., 1996). This may account for the PKA-
D1 receptor agonists, through activation of PKA, en- induced potentiation of the glutamate response origi-
hance currents evoked by NMDA in medium spiny neu- nally observed in hippocampal neurons (Greengard et
rons (Cepeda et al., 1998). Studies in oocytes have indi- al., 1991; Wang et al., 1991). In acutely dissociated stria-
cated that the DARPP-32/PP-1 cascade is likely to be tal neurons, when AMPA currents are recorded in the
involved in mediating the effect of dopamine on NMDA whole-cell mode, a time-dependent reduction in current
receptor currents (Blank et al., 1997). NMDA receptor amplitude is observed (Yan et al., 1999). This current
currents are potentiated by PKA activation in oocytes ªrundownº is prevented by the application of a dopa-
injected with mRNA from neostriatum but not from hip- mine D1 receptor agonist. Elucidation of the postrecep-
pocampus. Downregulation of DARPP-32 using anti- tor mechanisms that underlie this effect implicate
sense oligonucleotides in oocytes injected with striatal DARPP-32, spinophilin, and PP-1. Infusion of a phos-
mRNA negates the PKA-dependent enhancement of phorylated, active form of DARPP-32 mimics the effect
NMDA receptor currents. In contrast, coinjection of of the D1 agonist. In addition, the effect of the D1 agonist
DARPP-32 mRNA with hippocampal mRNA confers reg- on AMPA receptor current is greatly reduced in striatal
ulation of NMDA receptor currents by PKA. The simplest neurons from DARPP-32 knockout mice. Dopamine, via
interpretation of these studies is that increased NR1 activation of PKA and inhibition of PP-1, synergistically
phosphorylation mediated by activation of PKA and inhi-
increases phosphorylation of the AMPA receptor. To-
bition of PP-1 directly contributes to the increase in
gether, these results suggest that decreased dephos-
NMDA receptor currents. However, the precise role of
phorylation of the AMPA receptor results in increasedNR1 phosphorylation in regulating the properties of the
channel activity (Figure 7).NMDA receptor has not been elucidated. Other studies
Disruption of the spinophilin/PP-1 targeting complexin medium spiny neurons have indicated that inhibitors
also resulted in modulation of AMPA channel currents.of L-type Ca21 channels markedly reduce (but do not
These experiments were enabled by the mapping of theeliminate) the ability of dopamine to regulate NMDA re-
docking motif for PP-1 on spinophilin (Figure 4B). Aceptor currents (Cepeda et al., 1998). D1 agonists en-
peptide was identified that mimics the docking motifhance L-type Ca21 currents in medium spiny neurons,
and that antagonizes the interaction of PP-1 with full-an effect that is likely to be mediated by direct phosphor-
length spinophilin in vitro without affecting the activityylation of the channel by PKA and inhibition of PP-1 by
of PP-1 (Hsieh-Wilson et al., 1999). When this peptideDARPP-32 (Surmeier et al., 1995). Thus, activation of
is infused into medium spiny neurons, the rundown inthe DARPP-32/PP-1 cascade by dopamine will lead to
AMPA channel current is prevented. In this case, theparallel increases in the phosphorylation of both NMDA
effect is not attributable to PP-1 inhibition but rather toNR1 subunits and L-type Ca21 channels and, in an inter-
the disruption of PP-1 targeting, i.e., the removal ofdependent manner, to an increase in intracellular Ca21
PP-1 from a close interaction with AMPA channels. Thislevels (Figure 6). The increase in Ca21 levels will, in turn,
prevents channel dephosphorylation and the associatedpresumably activate PP-2B and dephosphorylate DARPP-
32 as part of a negative feedback mechanism. loss of activity (Figure 7). In the neostriatum, cortex, and
Neuron
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Figure 7. Regulation of AMPA-Type Glutamate Receptors by DARPP-32 and Spinophilin
Model illustrates how regulation of PP-1 could account for the ability of DARPP-32 and spinophilin to control AMPA channels.
(Top) Spinophilin, by binding to an unidentified intermediate protein (not shown), localizes PP-1 in the vicinity of the AMPA channel. Under
basal conditions, the PP-1/spinophilin complex maintains the AMPA channel (or an associated protein) in a dephosphorylated, low-activity
state.
(Bottom left) Following D1 receptor stimulation, AMPA channel phosphorylation is increased due both to direct PKA phosphorylation and to
PKA/phospho-DARPP-32-mediated inhibition of PP-1. This synergistic increase in phosphorylation stimulates AMPA channel activity. The
kinase anchoring protein (AKAP) believed to localize PKA in the vicinity of the AMPA receptor (Rosenmund et al., 1994) is not shown.
(Bottom right) Activity of the AMPA channel can be increased by disrupting the spinophilin/PP-1 interaction using a peptide encompassing
the high-affinity PP-1 docking motif of spinophilin.
hippocampus, immunoelectron microscopy has indi- effect on L-type Ca21 channels described above, D1
receptor agonists reduce N- and P-type Ca21 currentscated that both dopamine D1 and D2 receptors can be
found in dendritic spines (Bergson et al., 1995; Yung (Surmeier et al., 1995). The effect of D1 agonists is atten-
uated in medium spiny neurons obtained from DARPP-et al., 1995). Thus, PP-1 targeting may be particularly
relevant with regard to the dopaminergic modulation of 32 knockout mice (Fienberg et al., 1998), suggesting a
role for the DARPP-32/PP-1 cascade in the regulationthe postsynaptic glutamate response.
Regulation of Voltage-Gated Ion Channels of N- and P-type Ca21 channels. Paradoxically, the inhib-
itory effect of D1 receptor activation is blocked eitherD1 and D2 receptor agonists reduce the amplitude of
Na1 current in most striatal medium spiny neurons (Sur- by PKA inhibitors or PP-1 inhibitors, including phospho-
DARPP-32 (Surmeier et al., 1995). These results suggestmeier and Kitai, 1993; Schiffmann et al., 1995). The inhib-
itory effect of D1 receptor stimulation is observed at a model in which PP-1 activity is increased by PKA,
perhaps through regulation of a PP-1-targeting subunit,hyperpolarized membrane potentials and reduces the
responsiveness of medium spiny neurons to excitatory as a consequence of which the dephosphorylation of
N- and P-type Ca21 channels is increased.input. Inhibition of Na1 current requires PKA, and in-
jection of phospho-DARPP-32, but not dephospho- Regulation of Synaptic Plasticity
At glutamatergic corticostriatal synapses, the inductionDARPP-32, into striatal neurons mimics the effect of
dopamine acting at D1 receptors (Schiffmann et al., of long-term depression (LTD) requires endogenous do-
pamine. Moreover, in striatal slices prepared from dopa-1995, 1998). Moreover, the effect of D1 receptor stimula-
tion on Na1 current is significantly attenuated in medium mine-depleted animals, LTD is restored by the simulta-
neous activation of D1 and D2 receptors (Calabresi et al.,spiny neurons from DARPP-32 knockout mice (Fienberg
et al., 1998). In vitro and in intact cells, PKA directly 1992). Dopamine also regulates long-term potentiation
(LTP) in hippocampus (Frey et al., 1991; Huang and Kan-phosphorylates Na1 channels, and this leads to inhibi-
tion of channel activity (Li et al., 1992). It appears likely del, 1995; Otmakhova and Lisman, 1996; Kusuki et al.,
1997). In this brain region, PP-1 has been identified asthat phospho-DARPP-32, by inhibiting PP-1, contrib-
utes to the D1 receptor±mediated inhibition of Na1 chan- a downstream effector in NMDA receptor±dependent
induction of LTD (Mulkey et al., 1994). Conversely, inhibi-nels by reducing their dephosphorylation (Schiffmann
et al., 1998). tion of PP-1 is required to permit LTP induction in hippo-
campal neurons (Blitzer et al., 1995, 1998). SubstratesPhosphorylation of N- and P-type Ca21 channels is
also associated with altered activity. In contrast to the for PP-1 that are likely to be involved in regulation of
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synaptic plasticity include Ca21/calmodulin-dependent al., 1996). In addition to these changes in acute re-
protein kinase II (Silva et al., 1992; Lledo et al., 1995; sponse, the long-term induction of c-fos isoforms, nor-
Mayford et al., 1996; Rotenberg et al., 1996), the GluR1 mally seen in response to chronic cocaine administra-
subunit of the AMPA receptor (Barria et al., 1997), and tion, was not observed in knockout animals. These
the cAMP response element binding protein (CREB) deficits in the biochemical responses to psychostimu-
(Bourtchuladze et al., 1994; Bito et al., 1996). Thus, PP-1 lants may be related to a reduced propensity of DARPP-
may influence the induction and maintenance of LTP 32 knockout mice to develop an addiction to these
and LTD via several different mechanisms. Studies using drugs. Thus, both place preference associated with co-
DARPP-32 knockout mice indicate that plasticity at cor- caine administration and cocaine self-administration are
ticostriatal synapses is under the control of DARPP- attenuated in the DARPP-32 mutant mice (V. Zachariou
32 (P. Calabresi, personal communication). Spinophilin and M. Picciotto, personal communication; L. Gold and
may also regulate synaptic plasticity, since it appears G. Koob, personal communication).
to control AMPA channels (see above), which carry An additional insight into the biological function of
much of the increase in current following LTP induction the DARPP-32/PP-1 pathway was obtained from the
(Kauer et al., 1988; Muller and Lynch, 1988). above drug treatment paradigms. The response deficits
that are seen in the mutant mice at low drug doses
Role of the DARPP-32/PP-1 Cascade in Mediating are partially overcome at higher doses. These results
the Actions of Psychoactive Drugs suggest that supraphysiological activation of the dopa-
Drugs of Abuse mine signaling pathway can stimulate changes in the
The dopaminergic neurotransmitter system is a major phosphorylation state and activity of physiological ef-
target for the reinforcing properties of drugs of abuse, fectors that are sufficiently large to eliminate the need
including cocaine, amphetamine, and opiates. In accor- for positive feedback amplification from the DARPP-32/
dance with this, lesioning of the dopamine system, or PP-1 cascade.
the administration of dopamine receptor ligands and Antidepressant Drugs
second messengers, interferes with the normal course Antidepressant drugs (including lithium, imipramine, and
of drug self-administration in animals (Self and Nestler, tranylcypromine), when administered to rats, all induce a
1995). All three classes of these drugs, through distinct robust increase in DARPP-32 levels selectively in frontal
mechanisms, induce an increase in dopaminergic neu- cortex but not in other brain regions. This commonality
rotransmission at the receptive fields of midbrain dopa-
of effect suggests that the upregulation of DARPP-32
mine neurons (Koob et al., 1998) and regulate the phos-
expression may contribute to the clinical efficacy ofphorylation of DARPP-32 (Figure 1). In intact animals,
these drugs (Guitart and Nestler, 1992).both cocaine and amphetamine increase DARPP-32
Antischizophrenic Drugsphosphorylation in neostriatum. In neostriatal slices, a
Although the dopamine system is implicated in the ac-
m opioid receptor agonist inhibits DARPP-32 phosphor-
tion of drugs used in the treatment of schizophrenia,ylation induced by D1, but not by adenosine A2A, receptor
neither the underlying biochemical basis for the condi-stimulation. Conversely, a d receptor agonist inhibits
tion nor the mechanism whereby dopamine receptorDARPP-32 phosphorylation induced by activation of A2A,
antagonists provide clinical benefit is understood (An-but not D1, receptors (Lindskog et al., 1999). These re-
dreasen, 1996). Drugs used in the treatment of schizo-sults are consistent with a selective expression of m
phrenia induce catalepsy when administered to rodents.and d opioid receptors in striatonigral and striatopallidal
This behavioral response is severely attenuated in theneurons, respectively.
DARPP-32 knockout mice in response to the neurolepticResults from the analysis of DARPP-32 knockout mice
raclopride, a D2 receptor antagonist (Fienberg et al.,have also indicated an essential role for the DARPP-32/
1998). At the molecular level, both haloperidol, a ªtypicalPP-1 pathway in the behavioral actions of drugs of
antipsychotic,º and clozapine, an ªatypical antipsychotic,ºabuse (Table 1). Acute administration of cocaine or
increase phosphorylation of DARPP-32 in rats. Raclo-D-amphetamine normally leads to increases in locomo-
pride blocks the D2-mediated opposition to D1-stimu-tor activity. These responses are severely attenuated in
lated phosphorylation of DARPP-32 (Nishi et al., 1997).DARPP-32-deficient animals. In contrast, the sensitiza-
Raclopride has a similar effect on the phosphorylationtion of the locomotor response to repeated cocaine ad-
of the NMDA receptor subunit NR1 (Snyder et al., 1998).ministration is heightened in the DARPP-32 knockout
Together, these results suggest that the clinical effectsanimals (Fienberg et al., 1998; Hiroi et al., 1999). These
of antipsychotic drugs may involve modulation of theresults emphasize the distinct molecular mechanisms
state of phosphorylation and activity of the NMDA re-involved in the acute versus chronic effects of these
ceptor, through a mechanism involving DARPP-32 (seedrugs. In addition, they further indicate that DARPP-32
Figure 6).may subserve either a positive or a negative feedback
role, depending on the particular system being ex-
Concluding Remarksamined.
The DARPP-32/PP-1 cascade plays an obligatory roleBiochemical responses to drugs of abuse are also
in mediating actions of dopamine, be they excitatory oraltered in DARPP-32 knockout mice. Neostriatal induc-
inhibitory, at both D1 and D2 classes of receptor. Varioustion of the immediate-early response gene, c-fos, is nor-
biochemical, physiological, and behavioral effects of do-mally seen following acute amphetamine administration,
pamine, antipsychotic drugs, and drugs of abuse arebut this induction is attenuated in the DARPP-32 mutant
greatly reduced or abolished in mice with a targetedanimals. The effect may be due to reduced phosphoryla-
deletion of the DARPP-32 gene. In addition to dopamine,tion and activation of CREB in response to amphet-
numerous other neurotransmitters that regulate the ex-amine, since CREB drives c-fos expression and is nega-
tively regulated by PP-1 (Hagiwara et al., 1992; Bito et citability of dopaminoceptive neurons also utilize the
Neuron
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A., Greengard, P., and Spiess, J. (1997). The phosphoproteinDARPP-32/PP-1 cascade to achieve their biological ef-
DARPP-32 mediates cAMP-dependent potentiation of striatalfects.
N-methyl-D-aspartate responses. Proc. Natl. Acad. Sci. USA 94,The DARPP-32/PP-1 cascade regulates the state of
14859±14864.
phosphorylation and activity of all of the physiological
Blitzer, R.D., Wong, T., Nouranifar, R., Iyengar, R., and Landau, E.M.
effectors in dopaminoceptive neurons examined to date. (1995). Postsynaptic cAMP pathway gates early LTP in hippocampal
These include a variety of neurotransmitter receptors, CA1 region. Neuron 15, 1403±1414.
voltage-gated ion channels, transcription factors, and Blitzer, R.D., Connor, J.H., Brown, G.P., Wong, T., Shenolikar, S.,
an electrogenic ion pump. The convergence of a large Iyengar, R., and Landau, E.M. (1998). Gating of CaMKII by cAMP-
regulated protein phosphatase activity during LTP. Science 280,number of signal transduction pathways on the DARPP-
1940±1942.32/PP-1 cascade and the resulting coordinated regu-
Blumer, K.J., and Johnson, G.L. (1994). Diversity in function andlation of a variety of effectors provide a molecular
regulation of MAP kinase pathways. Trends Biochem. Sci. 19,framework for understanding the ability of medium spiny
236±240.neurons to integrate the vast amount of information en-
Bourtchuladze, R., Frenguelli, B., Blendy, J., Cioffi, D., Schutz, G.,tering the neostriatum and to respond in a physiologi-
and Silva, A.J. (1994). Deficient long-term memory in mice with a
cally coherent fashion. Undoubtedly, other components targeted mutation of the cAMP-responsive element-binding protein.
of the DARPP-32/PP-1 signaling cascade will be found Cell 79, 59±68.
in dopaminoceptive neurons, including additional neu- Burnett, P.E., Blackshaw, S., Lai, M.M., Qureshi, I.A., Burnett, A.F.,
rotransmitters as well as physiological effectors. Several Sabatini, D.M., and Snyder, S.H. (1998). Neurabin is a synaptic pro-
tein linking p70 S6 kinase and the neuronal cytoskeleton. Proc. Natl.PP-1 targeting proteins have been identified, one of
Acad. Sci. USA 95, 8351±8356.which appears to be responsible for targeting PP-1 to
Calabresi, P., Mercuri, N., Stanzione, P., Stefani, A., and Bernardi,dendritic spines. These targeting proteins contain con-
G. (1987). Intracellular studies on the dopamine-induced firing inhibi-sensus sequences for regulation by phosphorylation,
tion of neostriatal neurons in vitro: evidence for D1 receptor involve-
providing still further potential sites for regulation. Eluci- ment. Neuroscience 20, 757±771.
dation of the numerous biochemical steps that either
Calabresi, P., Maj, R., Pisani, A., Mercuri, N.B., and Bernardi, G.
regulate or are regulated by the DARPP-32/PP-1 cas- (1992). Long-term synaptic depression in the striatum: physiological
cade provides novel candidates for the etiology of ill- and pharmacological characterization. J. Neurosci. 12, 4224±4233.
nesses associated with abnormalities of dopaminergic Cepeda, C., and Levine, M.S. (1998). Dopamine and N-methyl-D-
aspartate receptor interactions in the neostriatum. Dev. Neurosci.neurotransmission, including schizophrenia, ADHD, Par-
20, 1±18.kinson's disease, and drug addiction. Moreover, the re-
Cepeda, C., Buchwald, N.A., and Levine, M.S. (1993). Neuromodula-sults reveal novel targets for the development of drugs
tory actions of dopamine in the neostriatum are dependent uponfor the treatment of these various illnesses. Finally, clari-
the excitatory amino acid receptor subtypes activated. Proc. Natl.fication of the molecular mechanisms that underlie the
Acad. Sci. USA 90, 9576±9580.
regulation by dopamine of biological responses in target
Cepeda, C., Colwell, C.S., Itri, J.N., Chandler, S.H., and Levine, M.S.
neurons, and of the interactions of dopamine with other (1998). Dopaminergic modulation of NMDA-induced whole cell cur-
neurotransmitters in these dopaminoceptive cells, pro- rents in neostriatal neurons in slices: contribution of calcium con-
ductances. J. Neurophysiol. 79, 82±94.vide a template for studying the actions, interactions,
and pathophysiology of signal transduction pathways Craven, S.E., and Bredt, D.S. (1998). PDZ proteins organize synaptic
signaling pathways. Cell 93, 495±498.in other regions of the brain.
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